Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

References

• Jaffe ES, Harris N, Stein H, Vardiman JW, editors. World Health Organization classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
   Google Scholar
• Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362–71.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148–52.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27:2991–9.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, et al., editors. WHO classification of tumours of haematopoietic and lymhoid tissues. Lyon, France: IARC press; 2008.
   Google Scholar
• Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–8.
   PubMed Web of Science ®Google Scholar
• Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758–67.
   PubMed Web of Science ®Google Scholar
• Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360–5; Reply, Haematologica. 2012;97:e7–8.
   PubMed Web of Science ®Google Scholar
• Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360–5; Comment, Haematologica. 2012;97:e5–6.
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60–70.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol. 1998;61:71–6.
   PubMed Web of Science ®Google Scholar
• Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004;101:2239–46.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004;89:1306–13.
   PubMed Web of Science ®Google Scholar
• Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863–6.
   PubMed Web of Science ®Google Scholar
• Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520–7.
   PubMed Web of Science ®Google Scholar
• Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma. 1996;22 (Suppl. 1):41–5.
   PubMed Web of Science ®Google Scholar
• Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Green AR, et al. A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematol Am Soc Hematol Educ Program. 2000;1:51–68.
   Google Scholar
• Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features–a clinicopathological study on 272 patients. Histol Histopathol. 2003;18:93–102.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Iannitto E, Iannitto E, Porcasi R, Ingrao S, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911–9.
   PubMed Web of Science ®Google Scholar
• Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774–81.
   PubMed Web of Science ®Google Scholar
• Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137–43.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452–66.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–23.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270–6.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645–51.
   PubMed Web of Science ®Google Scholar
• Hultdin M, Sundstrom G, Wahlin A, Lundstrom B, Samuelsson J, Birgegard G, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007;24:63–70.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–9.
   PubMed Web of Science ®Google Scholar